Patent ID: 7906493

Claim:
A method of treatment of a condition associated with raised activity of the enzyme Core 2 GlcNAc-T comprising administration of an effective amount of a compound of the formula IV to a patient in need thereof: wherein Z is either a group of the formula VII: wherein: R 12 , R 13 , R 15 and R 28 each represent H; R 14 is H, or R 14 and R 33 taken together represent the second bond of a double bond joining adjacent carbon atoms; R 16 is H, or ═O; R 17 is H or —OH; R 18 is H or —OH; R 19 is H, or —CH 3 ; R 20 is —OH or C 1-6 alkoxy; R 21 is of the formula VIII; R 22 is H, —OH, or —OMe; R 23 is CH 2 H 4 OH, —CH 2 OH, —CH 3 or ═CH 2 ; R 24 is C 1-6 alkyl, C 1-6 acyl, or glucose; R 29 is H or —OH; R 32 is H or —OH; R 33 is H; and Y is O; or a group of the formula XI: wherein: R 12 , R 13 , R 15 and R 28 each represent H; R 14 is H, or R 14 and R 33 taken together represent the second bond of a double bond joining adjacent carbon atoms; R 16 is H, or ═O; R 17 , R 18 , R 25 , R 29 , R 31 , R 32 , and R 34 are independently selected from H and —OH; R 19 is H, or —CH 3 ; R 26 is —CH 2 H 4 OH, —CH 2 OH, —CH 3 or ═CH 2 ; R 33 is H; and X is O or NH; or a pharmaceutically acceptable salt, ester or tautomeric form thereof; and wherein said condition associated with raised activity of the enzyme Core 2 GlcNAc-T is selected from the group consisting of an inflammatory disease, diabetic cardiomyopathy, myocardial dysfunction, cancer, cancer metastasis and diabetic retinopathy.